Journal of Translational Medicine (Jul 2021)

Extracellular vesicle-derived AEBP1 mRNA as a novel candidate biomarker for diabetic kidney disease

  • Yiying Tao,
  • Xing Wei,
  • Yue Yue,
  • Jiaxin Wang,
  • Jianzhong Li,
  • Lei Shen,
  • Guoyuan Lu,
  • Yang He,
  • Shidi Zhao,
  • Fan Zhao,
  • Zhen Weng,
  • Xiahong Shen,
  • Ling Zhou

DOI
https://doi.org/10.1186/s12967-021-03000-3
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background A novel and improved methodology is still required for the diagnosis of diabetic kidney disease (DKD). The aim of the present study was to identify novel biomarkers using extracellular vesicle (EV)-derived mRNA based on kidney tissue microarray data. Methods Candidate genes were identified by intersecting the differentially expressed genes (DEGs) and eGFR-correlated genes using the GEO datasets GSE30528 and GSE96804, followed by clinical parameter correlation and diagnostic efficacy assessment. Results Fifteen intersecting genes, including 8 positively correlated genes, B3GALT2, CDH10, MIR3916, NELL1, OCLM, PRKAR2B, TREM1 and USP46, and 7 negatively correlated genes, AEBP1, CDH6, HSD17B2, LUM, MS4A4A, PTN and RASSF9, were confirmed. The expression level assessment results revealed significantly increased levels of AEBP1 in DKD-derived EVs compared to those in T2DM and control EVs. Correlation analysis revealed that AEBP1 levels were positively correlated with Cr, 24-h urine protein and serum CYC and negatively correlated with eGFR and LDL, and good diagnostic efficacy for DKD was also found using AEBP1 levels to differentiate DKD patients from T2DM patients or controls. Conclusions Our results confirmed that the AEBP1 level from plasma EVs could differentiate DKD patients from T2DM patients and control subjects and was a good indication of the function of multiple critical clinical parameters. The AEBP1 level of EVs may serve as a novel and efficacious biomarker for DKD diagnosis.

Keywords